Noninvasive ventilation (NIV) characteristics and parameters
| All patients | HCRF patients | HRF patients | p-value | |
| Subjects | 654 | 594 | 60 | |
| Duration of NIV therapy# days | 2.74 (1.51–4.73) | 2.76 (1.53–1.23) | 2.25 (1.23–5.95) | 0.56 |
| Total mask-on time¶ h | 34.0 (18.0–60.0) | 34.0 (18.2–60.0) | 34.0 (10.0–60.0) | 0.42 |
| Proportion of mask-on time % | 56.1 (41.2–69.5) | 55.2 (41.5–68.5) | 65.6 (33.7–85.2) | 0.07 |
| Settings | ||||
| Inspiratory pressure cmH2O | 18.0 (16.0–22.0) | 19.0 (16.0–22.0) | 15.0 (12.5–16.8) | <0.001 |
| Expiratory pressure cmH2O | 10 (8–14) | 10 (8–14) | 8.5 (6.5–10.0) | 0.07 |
| Pressure support cmH2O | 8 (5–15) | 8 (5–15) | 6 (4–11) | <0.001 |
| Out-of-protocol cessation of NIV+ | 37 (6) | 29 (4) | 8 (13) | 0.02 |
| Intolerance of treatment | 20 | 18 | 2 | |
| Change to palliative treatment intent | 12 | 7 | 5 | 0.10 |
| Treatment ineffective | 5 | 4 | 1 |
Data are presented as n, median (interquartile range) or n (%), unless otherwise stated. HCRF: hypercapnic respiratory failure; HRF: hypoxaemic respiratory failure. #: overall period where NIV was used (including mask-on and mask-off durations); ¶: cumulative period where the therapy was actually in use; +: therapy was stopped before clinical stability was achieved. p-values refer to differences between HCRF and HRF cohorts.